CN112672755A - 通用淀粉样蛋白相互作用基序(gaim) - Google Patents

通用淀粉样蛋白相互作用基序(gaim) Download PDF

Info

Publication number
CN112672755A
CN112672755A CN201980049538.2A CN201980049538A CN112672755A CN 112672755 A CN112672755 A CN 112672755A CN 201980049538 A CN201980049538 A CN 201980049538A CN 112672755 A CN112672755 A CN 112672755A
Authority
CN
China
Prior art keywords
gly
pro
ser
glu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980049538.2A
Other languages
English (en)
Chinese (zh)
Inventor
R.克里什南
E.艾斯普
M.普罗奇斯基
R.费希尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amir Treatment Co
Original Assignee
Proclara Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proclara Biosciences Inc filed Critical Proclara Biosciences Inc
Publication of CN112672755A publication Critical patent/CN112672755A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201980049538.2A 2018-06-15 2019-06-14 通用淀粉样蛋白相互作用基序(gaim) Pending CN112672755A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862685757P 2018-06-15 2018-06-15
US62/685,757 2018-06-15
US201862749499P 2018-10-23 2018-10-23
US62/749,499 2018-10-23
PCT/US2019/037179 WO2019241628A1 (en) 2018-06-15 2019-06-14 General amyloid interaction motif (gaim)

Publications (1)

Publication Number Publication Date
CN112672755A true CN112672755A (zh) 2021-04-16

Family

ID=67263052

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980049538.2A Pending CN112672755A (zh) 2018-06-15 2019-06-14 通用淀粉样蛋白相互作用基序(gaim)

Country Status (13)

Country Link
US (2) US11692017B2 (https=)
EP (2) EP3806884B1 (https=)
JP (1) JP7549536B2 (https=)
CN (1) CN112672755A (https=)
AU (1) AU2019287623B2 (https=)
BR (1) BR112020025111A2 (https=)
ES (1) ES2960493T3 (https=)
IL (1) IL279333B2 (https=)
MX (1) MX2020013525A (https=)
PL (1) PL3806884T3 (https=)
SG (1) SG11202012091WA (https=)
WO (1) WO2019241628A1 (https=)
ZA (1) ZA202100071B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113614101A (zh) * 2019-02-22 2021-11-05 洛约拉马利蒙特大学 淀粉样肽的变体
CN117343200A (zh) * 2023-12-04 2024-01-05 北京质肽生物医药科技有限公司 一种包含淀粉样核心多肽的融合蛋白、制备方法及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241628A1 (en) * 2018-06-15 2019-12-19 Proclara Biosciences, Inc. General amyloid interaction motif (gaim)
AU2023403257A1 (en) 2022-12-02 2025-06-12 Alzheon, Inc. Methods for treating neurodegenerative disorders with tramiprosate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093414A (zh) * 2011-11-29 2014-10-08 神经噬菌体制药股份有限公司 噬菌体的p3作为淀粉样蛋白结合剂的用途
WO2016090022A1 (en) * 2014-12-03 2016-06-09 Neurophage Pharmaceuticals, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
DK2906235T3 (en) 2012-10-02 2017-09-25 Proclara Biosciences Inc USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS
AU2014274253B2 (en) 2013-05-28 2018-06-14 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
WO2019241628A1 (en) * 2018-06-15 2019-12-19 Proclara Biosciences, Inc. General amyloid interaction motif (gaim)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093414A (zh) * 2011-11-29 2014-10-08 神经噬菌体制药股份有限公司 噬菌体的p3作为淀粉样蛋白结合剂的用途
WO2016090022A1 (en) * 2014-12-03 2016-06-09 Neurophage Pharmaceuticals, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal
CN107250154A (zh) * 2014-12-03 2017-10-13 普罗克拉拉生物科学股份有限公司 包含缺乏糖基化信号的经修饰的噬菌体g3p氨基酸序列的多肽

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113614101A (zh) * 2019-02-22 2021-11-05 洛约拉马利蒙特大学 淀粉样肽的变体
CN113614101B (zh) * 2019-02-22 2024-07-16 洛约拉马利蒙特大学 淀粉样肽的变体
US12522635B2 (en) 2019-02-22 2026-01-13 Loyola Marymount University Amyloid peptide variants
CN117343200A (zh) * 2023-12-04 2024-01-05 北京质肽生物医药科技有限公司 一种包含淀粉样核心多肽的融合蛋白、制备方法及其应用
CN117343200B (zh) * 2023-12-04 2024-01-30 北京质肽生物医药科技有限公司 一种包含淀粉样核心多肽的融合蛋白、制备方法及其应用

Also Published As

Publication number Publication date
PL3806884T3 (pl) 2023-11-20
MX2020013525A (es) 2021-02-26
US11692017B2 (en) 2023-07-04
ES2960493T3 (es) 2024-03-05
CA3102841A1 (en) 2019-12-19
US20230279064A1 (en) 2023-09-07
IL279333B2 (en) 2023-06-01
EP3806884A1 (en) 2021-04-21
AU2019287623B2 (en) 2024-11-07
US20210246179A1 (en) 2021-08-12
ZA202100071B (en) 2023-04-26
IL279333A (en) 2021-01-31
SG11202012091WA (en) 2021-01-28
EP4389154A3 (en) 2024-11-13
US12247055B2 (en) 2025-03-11
EP4389154A2 (en) 2024-06-26
JP2021527407A (ja) 2021-10-14
AU2019287623A1 (en) 2021-01-07
EP3806884C0 (en) 2023-08-02
WO2019241628A1 (en) 2019-12-19
EP3806884B1 (en) 2023-08-02
BR112020025111A2 (pt) 2021-04-06
JP7549536B2 (ja) 2024-09-11

Similar Documents

Publication Publication Date Title
US12247055B2 (en) General amyloid interaction motif (GAIM)
JP6283366B2 (ja) アミロイド結合剤としてのバクテリオファージ融合タンパク質のｐ３の使用
JP6440765B2 (ja) アミロイド結合剤としてのバクテリオファージのｐ３の使用
JP2020073610A (ja) グリコシル化シグナルを欠く改変バクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド
CA3102841C (en) General amyloid interaction motif (gaim)
HK40110180A (en) General amyloid interaction motif (gaim)
HK40049127A (en) General amyloid interaction motif (gaim)
HK40049127B (en) General amyloid interaction motif (gaim)
EA046070B1 (ru) Общий амилоид-взаимодействующий мотив (gaim)
RS56559B1 (sr) Upotreba p3 fuzionih proteina bakteriofaga kao vezujućih agenasa amiloida

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240628

Address after: liege

Applicant after: Amir Treatment Co.

Country or region after: Belgium

Address before: Massachusetts, USA

Applicant before: NEUROPHAGE PHARMACEUTICALS, Inc.

Country or region before: U.S.A.

TA01 Transfer of patent application right